Press Releases September 2, 2026 05:00 PM

RoboStrategy, Inc. Updates Net Asset Value as of August 31, 2026

RoboStrategy, Inc. reports a modest increase in Net Asset Value as of August 31, 2026, reflecting growth in robotics and AI investments.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
BOT

RoboStrategy, Inc., a Nasdaq-listed closed-end fund focused on robotics and physical AI private companies, announced its net asset value (NAV) per share rose to $11.35 as of August 31, 2026, representing a 0.27% increase month-over-month. The fund invests in leading innovators in robotics and autonomous systems to bridge public market access to private industry advancements.

RoboStrategy, Inc. Updates Net Asset Value as of August 31, 2026
BOT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • NAV increased by 0.27% to $11.35 per share as of August 31, 2026.
  • RoboStrategy invests in private robotics and physical AI companies including market leaders such as Figure AI, Apptronik, and Dyna Robotics.
  • The fund aims to provide public-market access to emerging innovators in robotics and autonomous systems, reflecting growth potential in the robotics and AI sectors.

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- RoboStrategy, Inc. (Nasdaq: BOT), a registered closed end fund providing exposure to private companies in robotics and physical AI, today announced its net asset value per share as of August 31, 2026.

As of August 31, 2026, RoboStrategy’s net assets applicable to common shares were $276,675,605.73, and the Fund’s NAV per share was $11.35.

This represents a 0.76% increase over the previously reported NAV of $274,578,031.45 on July 31, 2026. The new NAV per share represents a 0.27% increase over the previously reported $11.32.

About RoboStrategy, Inc.
RoboStrategy, Inc. is a closed-end management investment company built to power participation in the robotics and physical AI revolution. As robotics continue to penetrate into everyday life, RoboStrategy seeks to provide public-market access to the companies building that future. The fund focuses on high-conviction equity positions in what the fund believes are category-defining robotics and physical artificial intelligence innovators, including leaders such as Figure AI, Apptronik, Dyna Robotics, Dexmate, and other pioneers advancing autonomous systems, including those building the critical supply chain. RoboStrategy was created to bridge public markets with private innovation, enabling broader participation in technologies that are redefining labor, productivity, and the relationship between humans and intelligent machines.

For more information, visit robostrategy.co

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are not historical facts but are based on current expectations, estimates, projections, beliefs, and assumptions. Such statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially. The Fund undertakes no obligation to update or revise any forward-looking statements.

This press release is not an offer to sell or a solicitation of an offer to buy any securities. Any offering of securities may be made only by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Media Contact
Malory Van Guilder
[email protected]

Investor Contact
[email protected]


Risks

  • Forward-looking statements involve uncertainties and risks that could cause actual results to differ materially, including market volatility in robotics and AI investments.
  • The fund's performance depends on the success of private companies in rapidly evolving robotics and AI sectors, which carry inherent technological and market adoption risks.
  • Regulatory changes or market disruptions could impact liquidity and valuation of private holdings within the fund.

More from Press Releases

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026 Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference Sep 4, 2026